U.S. Electric Utilities Stock News

AptarGroup (ATR) just notched an important milestone, as its Bidose nasal spray system is the delivery platform for newly FDA approved CARDAMYST, a PSVT treatment, marking Aptar’s first dual Bidose combination product. See our latest analysis for AptarGroup. The CARDAMYST win lands at a mixed moment for investors, with AptarGroup’s share price at $123.63 after a solid 7 day share price return, but still weaker year to date momentum and a modestly positive 3 year total shareholder return. This...

Earlier in December 2025, nCino, Inc. announced that its Board of Directors had authorized a stock repurchase program of up to US$100 million, to be funded through existing cash, credit capacity and future cash flows. This new buyback comes as Insight Holdings Group fully exited its nCino position and broader technology-sector concerns about AI profitability weighed on investor sentiment. Against this backdrop of a major institutional exit, we’ll explore how nCino’s US$100 million buyback...

Inhibrx Biosciences (INBX) just gave investors a fresh look at its oncology pipeline, highlighting progress in INBRX-106 combo trials with Keytruda and ozekibart studies that could support meaningful FDA conversations in 2026. See our latest analysis for Inhibrx Biosciences. That steady clinical drumbeat has been mirrored in the market, with the share price at $83.09 after a 7.09 percent 1 month share price return and a powerful 444.85 percent year to date share price return, contributing to...

Telephone and Data Systems (TDS) just rewired its main credit agreement, extending the maturity date, stripping out certain SOFR interest add ons, and opening up an extra $300 million of secured and unsecured borrowing capacity. See our latest analysis for Telephone and Data Systems. The refinancing lands at a time when TDS’s share price has quietly rebuilt confidence, with an 11.05% year to date share price return and a striking 308.65% three year total shareholder return. This points to...

Simon Property Group (SPG) just drew fresh attention after Director Randall Lewis bought more shares, extending a steady streak of insider buying. Together with upbeat Taubman integration commentary, this is reshaping how investors are sizing up the REIT. See our latest analysis for Simon Property Group. Against this backdrop, Simon’s share price has quietly trended higher, with a solid year to date share price return and an even stronger multiyear total shareholder return suggesting momentum...

Impinj (PI) just cleared a key hurdle in its third quarter, beating earnings and revenue expectations while rolling out new Gen2X features designed to tackle counterfeiting and messy tag data across large enterprise deployments. See our latest analysis for Impinj. The upbeat quarter appears to be breathing life back into the story, with a 1 month share price return of nearly 15% helping offset a weaker 3 month patch and backing up a 5 year total shareholder return near 291%. This suggests...

NorthWestern Energy Group (NWE) has quietly outpaced many utility peers this year, with the stock up about 31% over the past year and roughly 24% year to date, catching income-focused investors attention. See our latest analysis for NorthWestern Energy Group. The latest leg higher has been driven more by a gradual shift in risk perception than by any single headline. The 90 day share price return of 17.23 percent and the 1 year total shareholder return of 31.10 percent suggest that momentum...

Ligand Pharmaceuticals (LGND) just put numbers around its 2026 outlook, projecting total revenue between $245 million and $285 million, with the bulk expected from royalty streams rather than product or contract sales. See our latest analysis for Ligand Pharmaceuticals. That forward look seems to be resonating with investors, with the share price now at $194.59 and a strong year to date share price return of 79.48 percent alongside a hefty 3 year total shareholder return of 190.30 percent,...

Butterfly Network (BFLY) is back on traders radar after a three way catalyst: a fresh licensing and co development deal with Midjourney, a director share purchase, and the launch of its Compass AI platform. See our latest analysis for Butterfly Network. Those catalysts have arrived against a backdrop of a sharp turnaround in sentiment. Butterfly’s 30 day share price return of 60.9 percent and 90 day gain of 67.7 percent contrast with a still modest 1 year total shareholder return of 1.6...

B. Riley Financial (RILY) just swung from a huge loss to solid profitability in its latest second quarter report, with revenue more than doubling and earnings per share flipping sharply back into positive territory. See our latest analysis for B. Riley Financial. The strong earnings rebound comes after a volatile stretch, with a sharp 1 day share price return of minus 17.5 percent and a 90 day share price return of minus 34.1 percent. The 3 year total shareholder return of minus 84.4 percent...

DiDi Global (OTCPK:DIDI.Y) is back in focus after launching 24/7 fully unmanned robotaxi trials in Guangzhou, raising fresh capital for its self-driving arm, completing a major buyback, and nearing closure on a sizeable U.S. IPO lawsuit settlement. See our latest analysis for DiDi Global. Despite the legal overhang easing and the robotaxi push signalling long term growth ambitions, DiDi Global’s 30 day share price return of 3.18 percent contrasts with a still weak 90 day share price return of...

Recently, BofA Securities highlighted The Cigna Group’s exposure to commercial health insurance and its scaled pharmaceutical platform, while Levi & Korsinsky began investigating potential federal securities law violations following Cigna’s disclosure of a higher Healthcare medical cost ratio that could pressure future profitability. This combination of optimism around pharmacy-driven earnings growth and scrutiny of rising medical costs underscores the tension between Cigna’s long-term...

NCR Voyix recently reported that it has retained its No. 1 global position in POS software installations across retail, reclaimed the top spot in new restaurant deployments, and reinforced its leadership in Grocery+ and convenience sectors. Alongside this industry leadership, the company’s latest quarterly results showed stronger recurring software and services revenue with improved profitability margins, reflecting progress in its platform-led, AI-enabled digital commerce strategy. Now,...

BioCryst Pharmaceuticals (BCRX) just picked up a meaningful catalyst, with the FDA clearing an oral pellet version of Orladeyo for children aged 2 to under 12 with hereditary angioedema, opening a newly addressable niche. See our latest analysis for BioCryst Pharmaceuticals. Despite this catalyst, BioCryst’s 1 year total shareholder return of around minus 2 percent and a 3 month share price return of roughly minus 10 percent suggest momentum has been fading, even as management pursues the...

SharpLink Gaming, Inc. recently completed a planned leadership transition appointing Joseph Chalom as CEO, while expanding its institutional-grade Ethereum treasury platform by more than doubling its ETH holdings and updating corporate bylaws. By increasing institutional ownership to over 30% and emphasizing Ethereum treasury management, the company is repositioning itself as a specialized, crypto-focused treasury operator within the broader digital asset ecosystem. Next, we’ll examine how...

Syndax Pharmaceuticals (SNDX) is back on traders radar after showcasing fresh data on its FDA approved cancer drugs Revuforj and Niktimvo at the high profile ASH hematology meeting in Orlando. See our latest analysis for Syndax Pharmaceuticals. The momentum around these ASH updates lines up with a strong run in the stock, with Syndax delivering a roughly 44% year to date share price return and a 59% total shareholder return over the last year, even as multi year total shareholder returns...

Nasdaq, Inc. recently moved to extend U.S. equity trading to 23 hours a day on its venues, filing with the SEC for an additional overnight session and outlining operational readiness for the expanded schedule by 2026. This push toward near-continuous trading highlights Nasdaq’s effort to reshape access to U.S. markets, particularly for global and after-hours investors, while reinforcing its identity as a technology-driven market operator. We’ll now explore how Nasdaq’s 23-hour trading push...

Ocular Therapeutix (OCUL) just sped up the playbook for its lead eye drug by planning to file an FDA application for AXPAXLI in wet AMD based on positive year one SOL-1 Phase 3 data. See our latest analysis for Ocular Therapeutix. The pivot to an earlier NDA comes as Ocular Therapeutix trades at $13.72, with a 1 month share price return of 16.67 percent and a year to date share price return of 56.98 percent, while its 3 year total shareholder return of 395.31 percent signals strong long term...

SS Innovations International (SSII) just hit a key milestone by filing a 510(k) submission with the FDA for its SSi Mantra surgical robot, aiming for faster, potentially lower cost entry into the US market. See our latest analysis for SS Innovations International. That progress comes after a choppy run, with a 1 day share price return of 6.7 percent and a 1 year total shareholder return of 17.4 percent suggesting momentum is starting to rebuild from a lower base. If this kind of medtech story...

Earlier in December 2025, GlaxoSmithKline notified IDEAYA Biosciences that it will terminate their 2020 collaboration and license agreement, returning the Werner Helicase (IDE275) and Pol Theta (IDE705) clinical programs to IDEAYA within about 90 days. This shift hands IDEAYA full control of two oncology assets while the company maintains its guidance that cash resources should last into 2030. Next, we’ll examine how GSK’s exit from the collaboration reshapes IDEAYA’s investment narrative,...

Wondering if Ally Financial at around $44 a share is still a value play after its big run, or if most of the upside is already priced in, you are not alone. The stock has climbed 18.4% over the last month, 24.8% year to date, and an impressive 106.8% over three years, which naturally raises questions about how much of the future has been pulled forward. Recent headlines have focused on Ally sharpening its digital banking strategy and doubling down on auto and consumer lending, while also...

Lennar (LEN) has just wrapped up FY 2025 with fourth quarter revenue of about $9.4 billion and basic EPS of $1.94, setting the tone for a year in which trailing twelve month revenue came in at roughly $34.2 billion alongside EPS of $8.06. The company has seen quarterly revenue move from around $9.9 billion in Q4 2024 to $9.4 billion in Q4 2025, while basic EPS shifted from $4.06 to $1.94 over the same stretch, leaving investors focused on how much of that topline scale is now flowing through...

CommScope Holding Company (COMM) has quietly staged a sharp turnaround, with shares up about 2,444% year to date and nearly 1,900% over the past year, catching many investors off guard. See our latest analysis for CommScope Holding Company. That surge has cooled a bit recently, with a 7 day share price return of negative 11.77 percent and a 30 day share price return of 7.63 percent. However, the 1 year total shareholder return of 189.89 percent still points to powerful momentum as investors...

Wondering whether Huntington Bancshares is still a buy at today's price, or if the easy gains are already behind it? This breakdown will help you decide, using a clear, valuation-first lens. After a solid run, the stock is up 15.6% over the last month and 15.9% over the past year, adding to a 79.4% gain over five years that has investors asking if it is getting ahead of itself. Recent headlines have focused on Huntington's continued push to grow its regional footprint and deepen customer...